+ 3.21
+ 0.93%
+ 0.69
+ 0.2%
+ 2.27
+ 0.54%
+ 0.35
+ 0.24%

Zoetis Investors May Need Patience To See Bull Thesis Play Out

July 26, 2017 11:08 am
Share to Linkedin Share to Twitter Share to Facebook Share to Print License More

After a more than 15-percent gain in Zoetis Inc (NYSE:ZTS) since the start of 2017, analysts at Deutsche Bank see little incremental upside in the near-term.

Gregg Gilbert downgraded Zoetis' stock from Buy to Hold with an unchanged $65 price target as it has handily outperformed the S&P index and most of the pharmaceutical space.

Zoetis should still be considered as a core long-term position, but investors could find a "more attractive" entry point for new money elsewhere, the analyst said. A $65 price target assumes mid-single digit revenue growth over the next few years along with operating margin expansion and higher earnings growth.

In the meantime, there's little reason for investors to view rival Eli Lilly and Co (NYSE:LLY)'s earnings report of being a concern, Gilbert added. Specifically, Eli Lilly's animal health division was lower in its recent quarter and highlighted by a 14 percent decline in food animal revenue.

However, Zoetis' portfolio isn't an apples-for-apples comparison to Eli Lilly's as the relationship between the two companies has "not been very consistent."

Finally, Zoetis is expected to at the very least meet consensus estimates in its second-quarter earnings report given its strong momentum along with a higher growth and margin profile versus its peers.

"We believe the stock better reflects the strong and durable revenue and earnings growth potential in the attractive Animal Health industry," the analyst emphasized.

Related Links:

Looking For A Better Entry Point, BMO Downgrades Zoetis Shares

Benzinga's Top Upgrades, Downgrades For July 26, 2017

For the latest in financial news, exclusive stories, memes follow Benzinga on Twitter, Facebook & Instagram. For the best interviews, stock market talk & videos, subscribe to our YouTube channel.

Related Articles

5 Biogen Analysts On FDA Approval Of Alzheimer's Drug Aduhelm, Broad Label, Pricing

Biogen Inc.'s (NASDAQ: BIIB) Alzheimer's treatment Aduhelm was approved by the FDA Monday, sending the company's shares up over read more

Lilly Awash In Catalysts, Pipeline Updates, Mizuho Says In Upgrade

Eli Lilly And Co (NYSE: LLY) received an upgrade from a Mizuho Securities analyst ahead of a key data readout in March. The Lilly Analyst: Vamil Divan upgraded Lilly shares from Neutral to Buy and increased the price target from $164 to $222. read more

BofA On Eli Lilly: Disappointing Q3 Comes In Otherwise Strong 2020

Eli Lilly And Co’s (NYSE: LLY) third-quarter results show the persisting impact of COVID-19 and pricing headwinds, according to BofA Securities. The Eli Lilly Analyst: Geoff Meacham maintained a Buy rating on Eli Lilly with a $180 price target.  read more

Regeneron Requests Emergency Use Authorization, Analysts See Coronavirus Antibodies As Earnings Driver In 2021

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) said Wednesday that it requested emergency use authorization from the FDA for its investigational coronavirus antibody cocktail. read more